ABBV
AbbVie Common Stock
ACTIONABLEMethodology gates passed
Position levels
Currenttoday
USD 246.04
Buy <=wait / entry
USD 224.00
Trim >=take some off
USD 262.00
Thesis breakA material adverse ruling on Skyrizi or Rinvoq patent challenges, a cut to full-...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 20% | 100 / 100 | 20.0 |
| Base case | 49% | 62 / 100 | 30.4 |
| Bear case | 31% | 10 / 100 | 3.1 |
| Weighted conviction | 53 / 100 - OPPORTUNISTIC BUY | ||
Top risks
- M&A activity: AbbVie to acquire Apogee Therapeutics for $10.9B equity value, adding late-stage IL-13 antibody zumilokibart and other immunology assets for atopic dermatitis and asthma
- Earnings performance: Q2 2026 GAAP diluted EPS $2.03 (+290.4%) and adjusted diluted EPS $3.65 (+22.9%), with raised 2026 revenue guidance to $67.6B
- Strategic licensing: AbbVie signs exclusive deal with RemeGen for RC148 (PD-1/VEGF bispecific) with $650M upfront